Skip to content

The Effects of Written Emotional Disclosure on Eating Disorder Pathology in a Clinical Eating Disordered Population

Study of the Efficacy of Written Emotional Disclosure on Eating Disorder Pathology

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00766558
Enrollment
29
Registered
2008-10-06
Start date
2009-06-30
Completion date
2013-07-31
Last updated
2017-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anorexia Nervosa, Bulimia Nervosa, Eating Disorder

Keywords

anorexia, bulimia, eating disorder not otherwise specified

Brief summary

A technique that has been found to be effective at relieving the physical and psychological symptoms associated with inhibiting emotions and emotional thoughts is written emotional disclosure. The goal of this study is to evaluate the effectiveness of written emotional disclosure on the remediation of eating disorder behaviour, cognitions, and management of emotions.

Detailed description

New Partial program participants complete a packet of questionnaires during their initial appointment, which will be used as baseline levels of eating disorder symptoms and psychological health. Participants will complete the writing as part of their eating disorder therapy. The writing will be completed individually. The writing will consist of continuous writing for fifteen minutes on three consecutive days. The experimental group will write about traumatic or stressful experiences, while the control group will objectively describe events. A post-writing packet of questionnaires will be completed one week after completing the writing. A follow-up evaluation will occur four-weeks after completion of the post-writing packet and will include completing a packet of questionnaires and debriefing.

Interventions

None listed

Sponsors

Milton S. Hershey Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
14 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Willing to sign consent form

Exclusion criteria

* Unwilling to sign consent form

Design outcomes

Primary

MeasureTime frame
Testing and behavioral changes6-weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026